The purpose of this study was to evaluate rectum motion during 3-Dimensional conformal radiation therapy (3D-CRT) in prostate cancer patients, to derive a planning volume at risk (PRV) and to correlate the PRV dose-volume histograms (DVH) with treatment complications.This study was conducted in two phases. Initially, the PRV was defined prospectively in 50 consecutive prostate cancer patients (Group 1) who received a radical course of 3-D CRT. Then, the obtained PRV was used in the radiotherapy planning of these same 50 patients plus another 59 prostate cancer patients (Group 2) previously treated between 2004 and 2008. All these patients' data, including the rectum and PRV DVHs, were correlated to acute and late complications, according to the Common Toxicity Criteria (CTC) v4.0.The largest displacement occurred in the anterior axis. Long-term gastrointestinal (GI) complications grade $2 were seen in 9.2% of the cases. Factors that influenced acute GI reactions were: doses at 25% (p 5 0.011) and 40% (p 5 0.005) of the rectum volume and at 40% of the PRV (p 5 0.012). The dose at 25% of the rectum volume (p 5 0.033) and acute complications $grade 2 (p 5 0.018) were prognostic factors for long-term complications. The PRV DVH did not correlate with late toxicity. The rectum showed a significant inter-fraction motion during 3D-CRT for prostate cancer. PRV dose correlated with acute gastrointestinal complications and may be a useful tool to predict and reduce their occurrence.
Introduction
In prostate cancer, randomized trials have shown a better biochemical control when higher doses of radiation therapy (RT) are delivered to the prostate (1, 2). The use of higher radiation doses, however, may result in a higher incidence of grade $2 complications in adjacent healthy organs, particularly the rectum (1-3).
A constant concern regarding highly conformal 3-Dimensional conformal RT (3D-CRT) or intensity modulated radiotherapy (IMRT) delivery to prostate tumors is the possible inter-and intra-fraction organ motion during treatment. To prevent potential geographical misses, a planning target volume (PTV) is created by adding a planning margin to the clinical target volume (CTV). The International Commission on Radiation Units and Measurements report 62 (ICRU 62) (4) also recommends the use of a margin around the organs at risk -planning organ at risk volume (PRV) -to account for their possible anatomical displacement plus set-up uncertainties during the same RT course.
PRV is more frequently used to organs considered vital structures, such as the spinal cord (5, 6) . However, the use of PRV for other structures may also be beneficial. The review of 141 computed tomography (CT) studies during irradiation of bladder cancer patients showed that a 6 mm anterior and a 5 mm posterior margin around the rectum would adequately account for the organ anatomical and physiological motion in 90% of the patients (7). The addition of an anterior margin increases the volume that receives higher doses of irradiation compared to a volume of rectum based on a dose-volume histogram (DVH) without margins (7). Others have shown that the use of a rectum PRV during irradiation for prostate cancer allows a better correlation with complications than the use of a DVH without margins (8).
The purpose of this study was to evaluate rectum motion during 3D-CRT in prostate cancer patients and to correlate rectal DVH, with (PRV) or without margins, with the acute and late complications associated with the treatment.
Material and Methods
This study was conducted in two phases. Initially, we defined an "optimal" PRV by prospectively studying rectal motion in 50 consecutive patients (Group 1) with biopsy-proven adenocarcinoma of the prostate and who received a radical course of 3-D CRT in our institution. Eligible patients were older than 20 years, had adequate follow-up information, no evidence of metastatic disease, no second malignancy, no history of previous bowel inflammatory disease and were not on immunosuppressive medication. All patients were required to sign a study-specific consent form. Pretreatment evaluation included a complete history and physical examination, blood work including PSA, and a bone scan and a CT scan of the abdomen and pelvis as part of their staging procedures. The derived PRV was then used to the radiotherapy replanning of these same 50 patients plus another 59 prostate cancer patients with similar characteristics (Group 2) and previously treated between 2004 and 2008 in our institution.
All patients were treated with 3-D CRT using megavoltage irradiation (6 MV). Patients underwent a treatment planning CT scan (5 mm thickness) in the supine position using a leg holder immobilization device. Preparation for the planning CT included an enema for rectal emptying and the oral intake of 500 ml of water 60 minutes before onset of the exam. The median radiation dose was 72 Gy (range: 70.2-73.8) prescribed to the 95% isodose surface and given at 1.8 Gy daily.The CTV was defined as the prostate and the proximal third of the seminal vesicles in patients with ,15% risk of seminal vesicle invasion. For the remaining patients, two CTVs were delineated. In the first plan, the CTV included the prostate and seminal vesicles (median dose: 50.4 Gy) and in the second phase only the prostate ($70.2 Gy). The PTV was established by expanding the CTV by 10 mm in all directions, except posteriorly where it was 8 mm. DVHs data for the rectum and bladder were generated for all patients. The rectal volume (whole rectum) was contoured from the anal border to the rectal-sigmoid junction. Rectal and bladder constraints were as per radiation therapy oncology group (RTOG) protocol 0415 (9), as follows: 15%, 25%, 35% and 50% of the bladder should receive less than 80 Gy, 75 Gy, 70 Gy and 65 Gy and 15%, 25%, 35% and 50% of the rectum should receive less than 75 Gy, 70 Gy, 65 Gy and 60 Gy, respectively. Patients were oriented to come to the treatment with a comfortably full bladder and an empty rectum. Isocenter verification was performed weekly with orthogonal portal films only. A previous study conducted at our institution by Giordani et al. (10) showed a systematic setup error of 1.99 mm in the craniocaudal direction, 1.37 mm laterally and 1.94 mm in the anteroposterior direction. The random setup errors observed were 1.25 mm, 0.84 mm and 1.1 mm, respectively.
For the definition of the PRV, group 1 patients were submitted to another planning pelvic CT scan between the 10 th and 15 th , and 25 th and 30 th RT delivery. The structures of interest were redrawn and by using digital reconstruction radiograph, the anterior, posterior and laterals rectal displacements were measured in relationship to the isocenter. The new measurements were then compared to the previous rectal position on the original planning CT scan. The median displacement, regardless of the direction, was documented. The measured value of each individual rectal axis motion was also defined as to include 90% of variations, which was defined as the "optimal" PRV ( Table I) . This PRV was used in the treatment replanning of groups 1 and 2 patients. DVHs were generated and the dose to 10%, 25%, 40% and 60% of the rectum and PRV volumes obtained. These volume percentages were selected because most rectal late toxicities are frequently associated with dose-volume parameters that include doses of $60 Gy (11).
During treatments, patients were evaluated weekly and questioned for acute gastrointestinal (GI) complaints. Posttreatment, patients were assessed at one month, every three months during the first two years of follow-up and once per semester thereafter. Acute complication was defined as those that occurred within 3 months post-RT and late complication, from the third month on. GI Complications were graded according to the Common Toxicity Criteria v4.0 (12).
All data were submitted to descriptive analysis. For the GI toxicity analysis, patient clinical characteristics (age, diabetes and hypertension) and treatment data (hormone therapy, risk classification, radiotherapy dose, number of fields used) were correlated to acute and late complications using Pearson's chi-square and Fisher's exact tests. The association between radiotherapy dose (40% of the rectal volume, 25% and 40% of the rectum PRV), age and acute and late GI complications was assessed using Student's T-test. For the other radiation dose variables Mann-Whitney test was used. Statistical analyses were performed by the software Statistical Package for the Social Sciences (SPSS) v. 15.0 for Windows and R-Program v 2.9.2. The level of significance was set at p # 0.05.
Results
Table I depicts the median rectal displacement in all axes for the first 50 patients. Of interest, in 53% of the patients, the rectal volume on the repeated scans was smaller than the original rectal volume as seen on the initial planning CT scan. The rectal volume in the planning CT scan and in the sequential two CT scan exams were: 88.87 cm 3 6 48.1, 80.44 cm 3 6 29.5 and 86.25 cm 3 6 32.6, respectively. There was no significant difference between rectum volumes of the planning CT and the second CT (p 5 0.218) or the third CT (p 5 0.671). The systematic and random errors for the anterior, posterior, right and left rectal wall were: 0.86 cm and 0.84 cm; 0.31 cm and 0.27 cm; 0.41 cm and 0.48 cm; 0.33 cm and 0.24 cm, respectively. Clinical and treatment characteristics of all 109 patients are listed in Table II . The median follow-up was 26 months (range: 6-54).
Treatments were well tolerated and most patients (70.6%) did not experience any acute GI complications. Grades 1 and 2 acute GI complications were seen in 19 (17.4%) and 13 patients (11.9%), respectively. No patient developed an acute grade 3 or higher complication. Late GI complications were also limited. Grades 1 and 2 were seen in 11 (10.1%) and 10 patients (9.2%), respectively. There were no grade 3 or 4 late complications.
Risk Factors for Complications
On univariate analysis, diabetes mellitus, systemic arterial hypertension, hormone therapy and age were not of prognostic significance for the development of acute or late GI complications grade 2. Patients who developed acute GI toxicity grade 2 or higher, did receive a higher radiation dose to the 25% (66.66 Gy 6 3.92, median 5 63.84 vs. 63.03 Gy 6 5.14, median 5 67.74, p 5 0.011) and 40% of the rectal volume (57.56 Gy 6 4.25 vs. 51.78 Gy 6 7.06, p 5 0.0015). Similarly, patients receiving a higher dose to 40% of the PRV volume had a higher rate of grade $2 acute GI toxicity (59.58 Gy 6 5.13 vs. 54.60 Gy 6 6.74, p 5 0.012).
Only patients with acute GI toxicity $grade 2 had a significant impact in the development of late GI complications (Table III) . Considering all the rectal and PRV DVHs studied, we observed that the dose to 25% of the rectal volume correlated with the development of late GI complications grade 2 (63.15 Gy 6 5.22, median 5 63.88 vs. 66.51 Gy 6 2.84, median 5 66.28, p 5 0.033). There was no correlation between the PRV DVHs and late GI toxicity. The radiation dose threshold to rectal and PRV volumes showing statistical significance for the development of acute and late GI complications are shown in Tables IV and V. We observed that the dose in 40% of the PRV volume had the most significant correlation with acute GI toxicity, with an odds ratio of 12.7.
Discussion
The rectal motion occurred mainly in the anterior axis, and an 11 mm margin would have been necessary to cover this displacement for 90% of all patients. Muren and co-workers (7) have also observed a larger anterior rectal displacement and recommended a larger anterior margin. They concluded that a 16 mm anterior and an 11 mm posterior margin would be adequate in 89% of the patients. These values are higher than those observed in our study. Using Mackenzie's formula (13), these authors concluded that a 6 and a 5 mm anterior and posterior margin, respectively, would encompass systematic errors of rectal motion in 90% of the patients (7).
The rectal DVH analysis shows that patients receiving higher doses to the 40% rectal and PRV volumes exhibited more moderate and severe acute GI complications. A higher dose to 25% of the rectal volume was associated with higher rates of both acute and late GI complications. Numerous studies have established a correlation between rectal dose and GI complications. Because of that, rectal volume constraints are recommended in order to prevent radiation-induced GI complications (14-18). In the present study we followed RTOG guidelines (9) for rectal constraints. However, it is worth mentioning that the boundaries of the rectal volume on planning CT varies among authors, making any type of comparison between series a complex and difficult exercise (19, 20) . Analyzing the studies that contour the rectum volume as in the present study, most rectal volume constraints recommendations were made particularly for volumes receiving high doses. Valdagni and coworkers (21) observed that GI toxicity depends on the percentage of rectum volume that receives doses between 60 and 70 Gy. However, in a recent report, the Quantitative Analysis of Normal Tissues Effects in the Clinic (QUANTEC) found a greater correlation between GI toxicity and doses higher than 70 Gy and rectal volumes smaller than 20% (11).
We defined a dose threshold for the rectum and PRV DVHs in order to minimize the risks for development of acute GI complications and observed that 25% and 40% of the rectum should not receive more than 65 and 55 Gy, respectively, whereas for chronic complications the dose for 25% of the rectal volume should not be higher than 64 Gy. Such values are closer to those established by QUANTEC, which recommends that 35%, 25% and 20% of the rectal volume should not receive doses higher than 60, 65 and 70 Gy, respectively (11).
Among all PRV DVHs values studied in our cohort, we observed that doses higher than 58 Gy in 40% of the PRV are associated with a higher incidence of acute GI complications. Considering all the cut off dose levels studied for the development of acute complications, the radiation dose to 40% of the PRV appears to be mathematically the most significant (OR 5 12.7), although the difference between the 40% PRV and the 40% rectal volume (OR 5 12.1) is small. This finding confirms the possible relevance of applying the rectal PRV volume concept in the radiation treatment planning for pelvic tumors. Muren et al. (8) observed that the rectum DVH was significantly associated with acute rectal toxicity in nine dose levels of the DVH curve and the PRV histogram with margins of 16 mm anterior and 11 mm posterior in 16 dose levels with a p value considerably lower between 55 and 70 Gy.
There is still a debate in the literature concerning the use of margins for organs with restriction dose-volume because the PRV volume is usually larger than the original organ's volume, making a proper correlation between the PRV DVH and the organ and its displacement a very difficult task (22). In our opinion, both rectum and PRV DVHs show limitations for an accurate determination of the delivered dose and its distributions in organs at risk that move during treatment; moreover, it is necessary to develop strategies that include geometrical uncertainties. In 53% of the repeated CT scans, the rectal volume was smaller than the initial volume used for planning. Other investigators have reported similar tendency for reduction of the rectal volume during radiotherapy (23-25). It is possible that the volume reduction observed during treatments may compensate for the anatomical displacement of the organ and explains the lack of correlation between the PRV DVHs and the development of late GI complications. To our knowledge, this is the first report looking at the potential predictive value of the PRV in the incidence of late GI complications.
Our data have to be viewed with caution and obviously do not represent a categorical and unequivocal observation on the lack of predicting value for the PRV DVH in late GI complications. Our study has potential limitations that may have impacted on the results. First, the number of patients studied is relatively small, and a larger sample could have lead to a possibly different correlation. Second, the number of toxicity events is also small, without sufficient statistical power. Finally, the number of repeated pelvic CTs during treatment delivery was limited and whether a higher number of imaging studies could lead to a different outcome remains to be established.
In conclusion, by analyzing the present results, we observed that PRV DVHs represented a prognostic factor for the development of acute, but not for late, GI toxicity and it may be used as a parameter to reduce the morbidity associated with this treatment especially considering that the intensity of acute reaction increases the probability of late toxicity which has a negative impact in the patients' quality of life. 
